Form 4: Mineralys CMO Executes Planned Stock Sales

Chief Medical Officer David Rodman sold over 22,000 shares of Mineralys Therapeutics under a pre-arranged trading plan in May 2026.

Summary

• David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics, executed a series of stock option exercises and subsequent sales between May 11 and May 13, 2026.
• A total of 22,575 shares were sold across three days at weighted-average prices ranging from $28.58 to $29.71 per share.
• The transactions were conducted under a Rule 10b5-1 trading plan, which was previously adopted on October 6, 2025.
• Following these transactions, Rodman directly owns 63,443 shares of common stock.
• The executive also retains significant derivative holdings, including over 236,000 unexercised stock options with various strike prices and expiration dates.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine liquidity event. While executive selling is rarely a positive catalyst, the use of a 10b5-1 plan and the retention of significant holdings mitigate negative sentiment.

Positives

• The sales were executed under a Rule 10b5-1 plan, providing an affirmative defense against potential insider trading concerns.
• The reporting person maintains a substantial equity stake in the company with 63,443 shares held directly.
• The executive holds a large volume of unexercised options (over 236,000), aligning long-term interests with shareholders.
• Option exercise prices as low as $1.08 indicate significant value creation since the grant dates.

Negatives

• The sale of 22,575 shares represents a reduction in the executive's direct common stock holdings.
• The weighted-average sale price showed a slight downward trend over the three-day period, from $29.71 to $28.58.

Risks

• Market perception of executive selling can sometimes create short-term downward pressure on the stock price.
• The reliance on automated trading plans means sales may occur regardless of immediate market conditions or upcoming company news.

Future Outlook

The use of a 10b5-1 plan suggests that the reporting person may have additional scheduled transactions in the future to manage personal liquidity and portfolio diversification.

Management Comments

• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes upon request.

Industry Context

StockSavvy.ai notes that it is standard practice for executives in clinical-stage biotechnology companies to utilize Rule 10b5-1 plans to manage the exercise of options and sale of shares, as these companies often experience high volatility and long periods of restricted trading windows.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is consistent with governance best practices at other Nasdaq-listed biotech firms such as Alnylam Pharmaceuticals or BridgeBio Pharma.
• The retention of a significant portion of equity post-sale is a positive signal compared to 'sell-all' strategies sometimes seen in smaller-cap entities.

Related Party Transactions

• The reporting person exercised options granted by the issuer and sold the resulting shares in the open market.

Stakeholder Impact

• Shareholders may see minor increased sell-side pressure in the short term due to the volume of shares sold.
• The transparency of the 10b5-1 plan helps maintain investor confidence in corporate governance.

Next Steps

• Monitor for subsequent Form 4 filings to determine if the 10b5-1 plan includes further monthly or quarterly sales.

Key Dates

Recommendation

The filing represents routine insider activity under a pre-arranged plan and does not provide new fundamental data regarding the company's clinical pipeline or financial runway that would warrant a change in investment thesis.

Keywords

Mineralys Therapeutics, MLYS, Insider Selling, Form 4, David Rodman, Stock Options, 10b5-1 Plan, Biotechnology, Executive Compensation